Extended Data Table 3 A. Ocular AEs in the 3.4 mg/kg SPLIT Dose Cohort; B. Belamaf Dosing in the 3.4 mg/kg SPLIT Dose Cohort; C. Pomalidomide Dosing in the 3.4 mg/kg SPLIT Dose Cohort

From: Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

  1. AE, adverse event; BCVA, best corrected visual acuity; No., number.